Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue
Use
Fluorescence in situ hybridization (FISH) testing for ROS1 allows for the detection of most ROS1 rearrangements, making it useful for identifying tumors that may be sensitive to directed therapy. ROS1 FISH testing may also aid the diagnosis of inflammatory myofibroblastic tumor, certain cutaneous melanocytic tumors, or other neoplasms when used with pathologic assessment.
Special Instructions
Not provided.
Limitations
This FISH test does not rule out other chromosome abnormalities. The test is not FDA-approved and should be used as an adjunct to existing clinical and pathologic information. Fixatives other than formalin may not be successful for FISH assays, and decalcified tissue success rate in FISH analysis is approximately 50%. If no FISH signals are observed, the case will indicate a lack of FISH results. A negative result does not exclude the presence of a ROS1 fusion or exclude possible sensitivity to targeted therapy.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Unknown CNV
Copy Number Region
LOINC Codes
- 81747-8 - Chr 6q22 region rearr Tiss FISH
- 50397-9 - Mol dx interp Bld/T Ql
- 69965-2 - Clinical cytogeneticist review
- 62356-1 - Chrom analy result (ISCN)
- 42349-1
- 31208-2 - Specimen source
- 80398-1 - Unique ID Current sample
- 85069-3 - Lab test method
- 48767-8 - Annotation comment Imp
- 18771-6 - Provider signing name
- 62364-5 - Test performance info Spec
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks prepared with alternative fixation methods will be attempted but are less favorable for FISH testing.
Causes for Rejection
All specimens will be evaluated for test suitability. Manage inappropriate fixation.